Abbott Laboratories (ABT) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Medical - Devices
EV/EBITDA
↓
16.07
↓-22% vs avg
5yr avg: 20.67
30Y Low4.9·High24.2
P/FCF
↓
24.20
↓-23% vs avg
5yr avg: 31.46
30Y Low4.6·High38.1
P/B Ratio
↓
3.23
↓-41% vs avg
5yr avg: 5.45
30Y Low1.6·High7.0
ROE
↑
30.9%
↓+55% vs avg
5yr avg: 19.9%
30Y Low2%·High44%
Debt/EBITDA
↓
1.52
↓-11% vs avg
5yr avg: 1.70
30Y Low0.4·High5.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ABT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Abbott Laboratories trades at 11.6x earnings, 63% below its 5-year average of 31.2x, sitting at the 41st percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 48%. On a free-cash-flow basis, the stock trades at 24.2x P/FCF, 23% below the 5-year average of 31.5x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $153.7B | $197.7B | $192.5B | $193.7B | $251.8B | $195.5B | $154.7B | $128.0B | $99.8B | $57.0B | $67.6B |
| Enterprise Value | $161.3B | $205.4B | $201.5B | $201.7B | $261.2B | $208.6B | $169.9B | $143.7B | $118.3B | $60.3B | $71.6B |
| P/E Ratio → | 11.57 | 14.80 | 33.66 | 28.08 | 35.72 | 43.80 | 42.17 | 53.98 | 211.37 | 40.86 | 15.28 |
| P/S Ratio | 3.66 | 4.71 | 4.80 | 4.44 | 5.85 | 5.65 | 4.85 | 4.19 | 3.64 | 2.73 | 3.31 |
| P/B Ratio | 3.23 | 4.13 | 4.96 | 5.25 | 6.99 | 5.93 | 4.94 | 4.17 | 3.21 | 2.75 | 3.17 |
| P/FCF | 24.20 | 31.13 | 38.05 | 24.82 | 29.11 | 34.16 | 34.39 | 26.10 | 22.51 | 27.36 | 36.44 |
| P/OCF | 17.96 | 23.10 | 26.51 | 20.21 | 23.90 | 24.75 | 25.21 | 20.32 | 17.92 | 17.78 | 22.80 |
P/E links to full P/E history page with 30-year chart
ABT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Abbott Laboratories's enterprise value stands at 16.1x EBITDA, 22% below its 5-year average of 20.7x. The Healthcare sector median is 14.2x, placing the stock at a 13% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.90 | 5.02 | 4.62 | 6.06 | 6.03 | 5.33 | 4.70 | 4.32 | 2.89 | 3.51 |
| EV / EBITDA | 16.07 | 20.45 | 20.82 | 17.35 | 20.51 | 24.21 | 22.35 | 20.18 | 23.70 | 13.11 | 16.20 |
| EV / EBIT | 23.64 | 26.97 | 27.37 | 23.40 | 30.30 | 36.75 | 34.72 | 39.91 | 38.04 | 35.15 | 21.31 |
| EV / FCF | — | 32.34 | 39.83 | 25.85 | 30.21 | 36.44 | 37.78 | 29.30 | 26.68 | 28.99 | 38.60 |
ABT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Abbott Laboratories earns an operating margin of 16.3%. Operating margins have compressed from 19.2% to 16.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 30.9% is exceptionally high. ROIC of 9.9% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.8% | 50.8% | 50.0% | 51.1% | 53.9% | 50.2% | 52.3% | 51.7% | 47.7% | 53.9% | 53.7% |
| Operating Margin | 16.3% | 16.3% | 16.0% | 19.2% | 21.4% | 15.3% | 14.4% | 12.6% | 7.2% | 15.6% | 14.5% |
| Net Profit Margin | 31.9% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% | 21.7% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 30.9% | 30.9% | 15.1% | 19.0% | 20.5% | 14.0% | 11.9% | 7.7% | 1.8% | 6.7% | 20.6% |
| ROA | 17.3% | 17.3% | 7.8% | 9.3% | 9.6% | 6.4% | 5.5% | 3.3% | 0.7% | 2.8% | 10.1% |
| ROIC | 9.9% | 9.9% | 10.4% | 13.9% | 15.1% | 8.6% | 7.4% | 6.0% | 4.0% | 9.9% | 8.7% |
| ROCE | 10.8% | 10.8% | 10.9% | 13.8% | 15.0% | 9.0% | 8.0% | 6.1% | 3.4% | 7.8% | 8.7% |
ABT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Abbott Laboratories carries a Debt/EBITDA ratio of 1.5x, which is manageable (53% below the sector average of 3.2x). Net debt stands at $7.7B ($15.3B total debt minus $7.6B cash). Interest coverage of 11.3x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.32 | 0.32 | 0.41 | 0.49 | 0.53 | 0.60 | 0.61 | 0.64 | 0.90 | 1.06 | 0.42 |
| Debt / EBITDA | 1.52 | 1.52 | 1.64 | 1.54 | 1.51 | 2.31 | 2.51 | 2.75 | 5.59 | 4.78 | 2.04 |
| Net Debt / Equity | — | 0.16 | 0.23 | 0.22 | 0.26 | 0.40 | 0.49 | 0.51 | 0.60 | 0.16 | 0.19 |
| Net Debt / EBITDA | 0.76 | 0.76 | 0.93 | 0.69 | 0.74 | 1.51 | 2.00 | 2.21 | 3.71 | 0.74 | 0.90 |
| Debt / FCF | — | 1.21 | 1.77 | 1.03 | 1.09 | 2.28 | 3.39 | 3.20 | 4.18 | 1.63 | 2.16 |
| Interest Coverage | 11.32 | 11.32 | 9.22 | 26.55 | 22.44 | 7.47 | 5.61 | 5.27 | 2.24 | 10.69 | 16.57 |
ABT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.67x means Abbott Laboratories can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.23x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.67 | 1.67 | 1.64 | 1.63 | 1.85 | 1.72 | 1.44 | 1.62 | 2.26 | 4.02 | 1.54 |
| Quick Ratio | 1.23 | 1.23 | 1.16 | 1.23 | 1.46 | 1.30 | 1.04 | 1.20 | 1.86 | 3.65 | 1.26 |
| Cash Ratio | 0.56 | 0.56 | 0.53 | 0.66 | 0.78 | 0.60 | 0.38 | 0.45 | 1.08 | 2.82 | 0.67 |
| Asset Turnover | — | 0.52 | 0.55 | 0.59 | 0.57 | 0.48 | 0.47 | 0.46 | 0.36 | 0.38 | 0.46 |
| Inventory Turnover | 3.33 | 3.33 | 3.06 | 3.46 | 3.85 | 3.44 | 3.52 | 3.89 | 3.98 | 3.95 | 3.63 |
| Days Sales Outstanding | — | 60.25 | 59.74 | 51.99 | 54.97 | 67.65 | 62.07 | 61.86 | 69.95 | 56.85 | 61.14 |
ABT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Abbott Laboratories returns 3.3% to shareholders annually — split between a 2.5% dividend yield and 0.8% buyback yield. The payout ratio of 28.6% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 8.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.5% | 1.9% | 1.8% | 1.7% | 1.3% | 1.3% | 1.5% | 1.5% | 1.9% | 2.7% | 2.1% |
| Payout Ratio | 28.6% | 28.6% | 62.1% | 47.7% | 45.3% | 57.0% | 61.6% | 83.4% | 387.6% | 109.9% | 32.6% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.6% | 6.8% | 3.0% | 3.6% | 2.8% | 2.3% | 2.4% | 1.9% | 0.5% | 2.4% | 6.5% |
| FCF Yield | 4.1% | 3.2% | 2.6% | 4.0% | 3.4% | 2.9% | 2.9% | 3.8% | 4.4% | 3.7% | 2.7% |
| Buyback Yield | 0.8% | 0.7% | 0.6% | 2.0% | 0.9% | 0.2% | 0.5% | 0.2% | 0.8% | 0.9% | 3.3% |
| Total Shareholder Yield | 3.3% | 2.6% | 2.5% | 3.7% | 2.2% | 1.5% | 1.9% | 1.7% | 2.7% | 3.6% | 5.4% |
| Shares Outstanding | — | $1.7B | $1.7B | $1.8B | $1.8B | $1.8B | $1.8B | $1.8B | $1.7B | $1.5B | $1.5B |
Peer Comparison
Compare ABT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ABTYou | $154B | 11.6 | 16.1 | 24.2 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $67B | 23.3 | 20.8 | 18.4 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 BDX | $52B | 24.7 | 14.0 | 19.5 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 BAX | $10B | -11.4 | 27.2 | 31.8 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 EW | $50B | 47.7 | 26.8 | 37.7 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
 SYK | $118B | 36.6 | 21.2 | 27.5 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into ABT consensus models and risk factors.
View Analysis
Should I Buy ABT?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ABT — Frequently Asked Questions
Quick answers to the most common questions about buying ABT stock.
What is Abbott Laboratories's P/E ratio?
Abbott Laboratories's current P/E ratio is 11.6x. The historical average is 19.6x. This places it at the 41th percentile of its historical range.
What is Abbott Laboratories's EV/EBITDA?
Abbott Laboratories's current EV/EBITDA is 16.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.4x.
What is Abbott Laboratories's ROE?
Abbott Laboratories's return on equity (ROE) is 30.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 22.6%.
Is ABT stock overvalued?
Based on historical data, Abbott Laboratories is trading at a P/E of 11.6x. This is at the 41th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Abbott Laboratories's dividend yield?
Abbott Laboratories's current dividend yield is 2.48% with a payout ratio of 28.6%.
What are Abbott Laboratories's profit margins?
Abbott Laboratories has 50.8% gross margin and 16.3% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Abbott Laboratories have?
Abbott Laboratories's Debt/EBITDA ratio is 1.5x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.